NSE/MANKIND

MANKINDMankind Pharma Ltd

Healthcare · NSE

₹2,125+0.98%

52-wk low52-WEEK RANGE52-wk high

₹1,927.4+10.3% from low ·-21.2% from high₹2,696.5

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

MANKIND+49.41% · 1Y

Range high ₹3,054.8Range low ₹1,242Latest ₹2,125Powered by TradingView · live NSE data

HealthcareLargecap

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite50/100

Performance

—

Not enough price history to score.

Valuation

High

Looks expensive vs the sector.

· P/E 49.2 — 30% above sector median 37.8

Growth

Medium

Steady but not standout growth.

· Revenue YoY +18.1%
· 3Y revenue CAGR +16.2%

Profitability

High

Showing good signs of profitability & efficiency.

· Net margin 16.3% — strong pricing power

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeB(61/100)

Durability

81/100

Financially resilient — strong quality + solvency profile.

Show 3 drivers

Piotroski F-score5/8 (63pt)
Altman Z" score7.44 (100pt)
Debt/Equity0.54 (83pt)

Valuation

40/100

Trading at a premium — growth must keep delivering to justify.

Show 4 drivers

P/E vs sector (49.2 / 37.8)130% (42pt)
P/B5.73 (70pt)
Dividend yield0.09% (2pt)
EV/EBITDA28.7 (23pt)

Momentum

62/100

Constructive setup — momentum building, not extended.

Show 4 drivers

DMA-trend alignmentsideways (50pt)
RSI (14)57.1 (98pt)
Price vs 200-DMA-8.0% (44pt)
MACD regimebullish (75pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)49.20

FAIR

CheapestP/E 49.2 near sector median.Most expensive

P/B5.73

FAIR

CheapestP/B 5.73 at 50th %ile of sector.Most expensive

EV/EBITDA28.72

OVERVALUED

Monthly seasonality

Avg monthly return over 3 years · historical — not a forecast

Best: Aug +7.46% · Worst: Jan -5.96%

Jan

-6.0%

33% win

Feb

+2.2%

67% win

Mar

+0.9%

67% win

Apr

+3.5%

100% win

May

-4.7%

50% win

Jun

+6.3%

Monthly return distribution

Distribution of 35 monthly returns

Mean

+1.60%

Median

+0.88%

Std dev

8.19%

Best

+25.5%

Worst

-15.4%

% positive

54%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 2

Strong net margin (16.3%)
High margin indicates pricing power + operating efficiency
Bankruptcy risk low (Altman Z″ 7.44)
Z″ above 2.60 sits squarely in the 'safe' zone

WEAKNESSES · 1

Premium to sector on P/E (+30%)
P/E 49.2 vs Healthcare median 37.8

OPPORTUNITIES · 0

No strong near-term catalysts visible

THREATS · 0

No immediate threats from the data

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+1.0%

+2.2%

-0.6%

-6.0%

-12.9%

-9.5%

+14.6%

10Y

—

Fundamentals

VALUATION

Market cap

₹87,619 Cr

P/E (TTM)

49.2

P/E (fwd)

—

next 12m

P/B

5.73

EV/EBITDA

28.7

Book value

—

per share

PROFITABILITY · QUALITY

ROE

—

ROCE

—

Net margin

16.3%

Op margin

—

Gross margin

—

D/E

0.54

GROWTH · MARKET

Rev YoY

+18.1%

Profit YoY

+4.1%

Div yield

0.09%

Payout

—

52w change

—

Beta

—

Pros and cons

Auto-derived from ratios · not a buy/sell recommendation

PROS · 1

+3-year revenue CAGR of 16.2%Sustained multi-year growth — not a one-quarter flash

CONS · 1

−Trades at a premium to sector on P/EP/E 49.2 vs Healthcare median 37.8 — priced for more growth than peers

Sector-relative context

Healthcare · 24 peers

P/E (TTM)

This stock

49.20

Sector median

37.85

Rank 15/24 (42th %ile)

ROE

This stock

—

Sector median

13.8%

—

P/B

This stock

5.73

Sector median

5.81

Rank 12/24 (54th %ile)

Quality score · Piotroski F-score

5 / 8

Decent quality — clears Piotroski bar

✓Profitable (positive net income)· Most basic check — company makes money
✓Positive return on assets· Assets generate returns
✓Positive operating cash flow· Profits are backed by real cash, not accruals
✗Operating CF exceeds net profit· Healthy cash conversion — no aggressive revenue recognition
✗Long-term debt decreased YoY· Deleveraging — lower refinancing risk
✓ROA improved YoY· Getting more productive with the asset base
✓Operating margin expanded YoY· Pricing power or cost discipline
✗

Forensic score · Altman Z″ (emerging markets)

Bankruptcy-risk predictor · 1995 Altman emerging-market revision

SAFE7.44

Z″ = 7.44 — well inside the SAFE zone. Low bankruptcy risk signal across liquidity, profitability and solvency inputs.

Component	Ratio	Weight	Contribution
Working Capital / Total Assets (A)	0.100	×6.56	0.656
Retained Earnings / Total Assets (B)	0.736	×3.26	2.400
EBIT / Total Assets (C)	0.206	×6.72	1.384
Book Equity / Total Liabilities (D)	2.856	×1.05	2.999

Zones: Z″ ≥ 2.60 safe · 1.10–2.60 grey · < 1.10 distress. Working capital proxied from reported cash + 10% buffer (exact 'current assets − current liabilities' line not ingested). Treat as directional.

Quarterly results

Last 5 quarters · ₹ Cr (Screener.in-grade depth)

Metric	2024-Q3	2024-Q4	2025-Q1	2025-Q2	2025-Q4
Revenue	3,061	3,199	3,008	3,570	3,567
Operating profit	747	629	560	628	697
OPM %	24.4%	19.7%	18.6%	17.6%	19.5%
Interest	7	221

Annual P&L

Last 4 years · ₹ Cr · all line items

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Revenue	7,782	8,749	10,259	12,207
Operating profit	1,884	1,642	2,239	2,516
OPM %	24.2%	18.8%	21.8%	20.6%
Interest	56	40	28	421

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
MANKINDTHIS Mankind Pharma Limited	₹2,125	-17.9%	87,619	49.2	5.73	—	0.54	+18.1%
DIVISLAB Divi's Laboratories Limited	₹6,229	+5.7%	1,66,714	67.2	10.81	16.1%	0.01	+12.3%
APOLLOHOSP Apollo Hospitals Enterprise Limited	₹7,699	+7.8%	1,10,096	61.0	12.11	19.8%	0.84	+17.2%
LUPIN Lupin Limited	₹2,326.1	+15.8%	1,06,756	23.0	5.43	—	0.32	+13.5%
DRREDDY Dr. Reddy's Laboratories Limited	₹1,235.7	+5.0%	1,02,626	18.2	2.76	16.1%	0.18	+4.4%
CIPLA Cipla Limited	₹1,240.8	-17.9%	99,317	21.9	3.02	13.8%	0.01	0.0%
MAXHEALTH Max Healthcare Institute Limited	₹1,007.65	-6.1%	98,448	69.7	9.85	—	0.33	+30.0%
AUROPHARMA Aurobindo Pharma Limited	₹1,386	+15.4%	80,209	23.0	2.29	9.9%	0.22	+9.4%
ALKEM Alkem Laboratories Limited	₹5,582	+11.6%	67,578	28.5	5.06	17.8%	0.17	+2.3%

ASK AXEL

Dig deeper into MANKIND

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for MANKIND — all in one sourced reply.

Ask free in chat

Run these tools on MANKIND

Historical return →

"If I had bought MANKIND in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on MANKIND

Brokerage + charges →

All-in cost for trading MANKIND

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	11.93	11.99	+0.5%
-2q	12.43	12.38	-0.4%
-3q	11.12	10.60	-4.6%
-4q	8.60	10.29	+19.7%

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Equity capital	40	40	40	41
Reserves	6,735	8,012	9,919	11,907
Borrowings	873	170	207	8,511
Other liabilities	—	—	23	20
Total liabilities	9,148	9,715	11,963	27,760
Fixed assets	2,448	3,076	3,171	3,259
CWIP	729	552	239	351
Investments	73	176	122	294
Other assets	—	—	66	92
Total assets	9,148	9,715	11,963	27,760

Metric	2022-FY	2023-FY	2024-FY	2025-FY
CF Operating	920	1,813	2,152	2,413
CF Investing	-1,369	-1,054	-2,082	-12,683
CF Financing	605	-740	5	10,233
Net cash flow	156	22	77	22
Free cash flow	-1,426	981	1,763	1,883

Metric	2025-FY	2024-FY	2023-FY	2022-FY
OPM %	20.6%	21.8%	18.8%	24.2%
Net margin %	16.3%	18.6%	14.7%	18.4%
ROE %	18.2%	21.2%	17.3%	21.2%
ROCE %	19.2%	26.4%	21.6%	26.5%
Debt / Equity	0.71	0.02	0.02	0.13
Interest coverage	7.0×	87.2×	42.5×	36.4×
Revenue growth YoY	+19.0%	+17.3%	+12.4%	—
Profit growth YoY	+4.1%	+49.2%	-10.6%	—

MANKINDMankind Pharma Ltd

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Quarterly results

Annual P&L

Peer comparison · Healthcare

Ask Axel about MANKIND

Recent news

Dig deeper into MANKIND

Run these tools on MANKIND

Technical snapshot

Earnings history + surprises

Dividends + splits history

Stock scorecard

Recent news

SWOT analysis

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Quarterly results

Annual P&L

Balance sheet

Cash flow statement

Ratios

Peer comparison · Healthcare